CRESCENT BIOPHARMA, INC. — Director's Dealing 2016

Mar 7, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2016-03-04

Reporting Person: Goldberg Mark Alan (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-04	Common Stock	P	10397	$4.7735	Acquired	11497	Direct

Footnotes

F1: The common stock was purchased by the reporting person in a series of open market transactions on the transaction date with a volume weighted average purchase price of $4.7735. The range of purchase prices for the transactions reported was $4.61 to $4.924 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.